Medical Devices APAC

APAC Antimicrobial Resistance Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Antimicrobial Resistance Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $631.0 Mn Placeholder estimate
Estimate 2025 $685.2 Mn 20% of the global market
Projected 2034 $1.44 Bn 110.1% Adds $754.6 Mn over 9 forecast years
CAGR 2025–2034 8.6% Faster than 36% of 173 Medical Devices markets here
Key players 5
  • APAC is 19.95% of the global market.
  • Among regions, the largest is North America at $1.90 Bn.
  • Fastest growing: APAC (this report) at 8.6% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$754.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Antimicrobial Resistance Diagnostics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $631.0 Mn — —
2025 (base) $685.2 Mn +$54.3 Mn —
2026 (forecast) $744.2 Mn +$58.9 Mn +8.6%
2027 (forecast) $808.2 Mn +$64.0 Mn +17.9%
2028 (forecast) $877.7 Mn +$69.5 Mn +28.1%
2029 (forecast) $953.1 Mn +$75.5 Mn +39.1%
2030 (forecast) $1.04 Bn +$82.0 Mn +51.1%
2031 (forecast) $1.12 Bn +$89.0 Mn +64.1%
2032 (forecast) $1.22 Bn +$96.7 Mn +78.2%
2033 (forecast) $1.33 Bn +$105.0 Mn +93.5%
2034 (forecast) $1.44 Bn +$114.0 Mn +110.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $3.43 Bn
  2. North America $1.90 Bn
  3. US $1.46 Bn
  4. APAC (this report) $685.2 Mn
  5. Europe $574.3 Mn
  6. China $322.7 Mn
  7. Canada $313.2 Mn
  8. Japan $216.0 Mn
  9. Latin America $157.0 Mn
  10. Germany $140.5 Mn
  11. Middle East $137.3 Mn
  12. Brazil $99.9 Mn
  13. UK $86.2 Mn
  14. France $87.1 Mn
  15. Italy $74.8 Mn
  16. Spain $64.6 Mn
  17. Saudi Arabia $63.7 Mn
  18. Ecuador $61.1 Mn
  19. India $60.5 Mn
  20. Mexico $48.2 Mn
  21. Australia $48.6 Mn
  22. Africa $47.0 Mn
  23. Russia $38.1 Mn
  24. New Zealand $29.1 Mn
  25. South Africa $25.9 Mn
  26. UAE $19.4 Mn
  27. Philippines $8.5 Mn
  28. Egypt $8.5 Mn
  29. Malaysia $6.0 Mn
  30. Hong Kong $5.2 Mn
  31. Singapore $4.4 Mn
  32. Thailand $4.2 Mn
  33. Kenya $2.7 Mn

Report snapshot

APAC Antimicrobial Resistance Diagnostics Market Analysis at a glance
Market size, 2025$685.2 Mn placeholder estimate
Forecast, 2034$1.44 Bn placeholder estimate
Growth (CAGR), 2025–20348.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersbioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), Accelerate Diagnostics, Inc., Thermo Fisher Scientific Inc. (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Antimicrobial Resistance Diagnostics Market Analysis Executive Summary

Antimicrobial resistance diagnostics show which antibiotics will work against an infection, helping doctors avoid ineffective drugs.

Key segments of the antimicrobial Resistance Diagnostics market include technology (Automated AST Systems, Molecular Resistance Tests and Rapid Phenotypic AST) and setting (Hospital Labs and Reference Labs).

Bar chart: Asia Pacific Antimicrobial Resistance Diagnostics market size, 2024–2034, placeholder estimates. $631.0 Mn in 2024, $685.2 Mn in 2025 and $1.44 Bn in 2034, 8.6% CAGR.
Asia Pacific Antimicrobial Resistance Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Antimicrobial Resistance Diagnostics Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antimicrobial Resistance Diagnostics market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the antimicrobial Resistance Diagnostics market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antimicrobial Resistance Diagnostics market.

Competitive Landscape for Antimicrobial Resistance Diagnostics Market in APAC

The antimicrobial Resistance Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Antimicrobial Resistance Diagnostics Market in APAC

Antimicrobial Resistance Diagnostics in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how antimicrobial Resistance Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Antimicrobial Resistance Diagnostics right now, from free public sources.

Latest research 20 papers since 2021 (worldwide)

  1. Vibrational spectroscopy and artificial intelligence for dynamic phenotypic characterization of antimicrobial resistance. Frontiers in cellular and infection microbiology, 2026
  2. Azithromycin in crisis: antimicrobial resistance, diagnostics gaps, and vaccine-linked stewardship for enteric infections in low- and middle-income countries. IJID regions, 2026
  3. Helicobacter pylori Management in ASEAN Countries: The Bangkok II Consensus Report. Journal of gastroenterology and hepatology, 2026
  4. The application of the CRISPR-Cas system in Pseudomonas aeruginosa infections. Molecular biology reports, 2026
  5. Toward standardized environmental detection of antibiotics and ARGs for regulatory interpretation and concern tiering. Frontiers in microbiology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Antimicrobial Resistance Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Antimicrobial Resistance Diagnostics market in Asia Pacific?
Placeholder estimate: about $685.2 Mn in 2025, rising to about $1.44 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Antimicrobial Resistance Diagnostics market in Asia Pacific growing?
Placeholder estimate: about 8.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Antimicrobial Resistance Diagnostics market report cover?
The report splits the market by technology (Automated AST Systems, Molecular Resistance Tests, Rapid Phenotypic AST), setting (Hospital Labs, Reference Labs) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Antimicrobial Resistance Diagnostics market?
Key players include bioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), Accelerate Diagnostics, Inc. and Thermo Fisher Scientific Inc..
What is driving the Antimicrobial Resistance Diagnostics market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antimicrobial Resistance Diagnostics market.
How much research is published on Antimicrobial Resistance Diagnostics?
PubMed lists 20 papers on Antimicrobial Resistance Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Antimicrobial Resistance Diagnostics in APAC? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in APAC

See all
Same topic, other categories

Related on antibiotics and diagnostics and lab testing

See the topic